EDX Medical Group plc (AIM: EDX), the Cambridge-based developer of digital diagnostic products and services for early disease detection, has announced the appointment of Martin Walton as Chief Executive Officer with immediate effect. Walton, who previously served as Deputy Chairman of the company, succeeds co-founder Dr Michael Hudson, who steps down from the board but will continue supporting the group as a consultant and Director of International Strategy and Partnerships. The board change signals what EDX Medical's chairman describes as a growth phase, with Walton's financial and commercial background expected to accelerate the company's commercial operations.
Key Points
- EDX Medical Group plc (AIM: EDX) is a Cambridge-based digital diagnostics company founded by Professor Sir Christopher Evans, OBE, and Dr Michael Hudson
- Martin Walton has been appointed Chief Executive Officer with immediate effect, transitioning from his role as Deputy Chairman
- Dr Michael Hudson stepped down from the EDX Medical board at close of business on 16 November 2026, moving to a consultancy and international partnerships role
- Investors should watch how Walton's financial and life sciences background shapes the company's commercial expansion strategy
Martin Walton Brings Over 35 Years of Finance and Life Sciences Experience to EDX Medical CEO Role
The announcement states that Martin Walton has more than 35 years of experience in finance and investment, including a role as vice chair, Europe and Asia Pacific, at a major Canadian bank. He has spent 15 years as an investor or officer in global life sciences companies, with his CV including Verona Pharma, Kymab, Arix Bioscience and Simbec-Orion. The company notes he has completed multiple corporate transactions in both private and publicly listed companies and has experience building and overseeing commercial operations, credentials the board considers directly relevant to EDX Medical's current stage of development.
Dr Michael Hudson Transitions to International Strategy Role After Co-Founding EDX Medical
Dr Michael Hudson, who co-founded EDX Medical alongside Professor Sir Christopher Evans, OBE, has stepped down from the board with effect from close of business on 16 November 2026. The announcement states he will continue to support the group as a consultant and Director of International Strategy and Partnerships. Chairman Dr Mike Owen acknowledged Hudson's contribution from the company's earliest days, indicating the international and partnerships role is considered significant to the group's ongoing growth. Hudson's continued involvement in a non-board capacity preserves institutional knowledge while enabling a leadership transition at the executive level.
Professor Sir Christopher Evans Appointed Deputy Chairman as EDX Medical Strengthens Its Board
Alongside the CEO change, the announcement confirms that Professor Sir Christopher Evans, OBE, founder and Chief Scientific Officer of EDX Medical, has been appointed Deputy Chairman. Evans, who has more than 30 years of experience as a medical and life sciences entrepreneur, noted that the board has recently been further strengthened by the addition of three highly experienced independent non-executive directors. EDX Medical operates its own facilities in Cambridge and holds strategic partnerships with organisations including Thermo Fisher EMEA Ltd, a world leader in life sciences solutions, as the group pursues cost-effective early disease detection and personalised treatment optimisation.




Please wait processing your request...